Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Novartis to Acquire Regulus in $1.7 Billion Deal
Novartis to Acquire Regulus in $1.7 Billion Deal · The Wall Street Journal

In This Article:

With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.